"Recombinant Human Activated Protein C Therapy of Sepsis: Translating Science into Practice"

**Pictures**
Speaker

Judith Jacobi, PharmD, FCCM, FCCP, BCPS
Location

Ruth Chris Steakhouse
1355 N Harbor Dr.
San Diego, CA 92101
(619) 233-1422

Map
Date Thursday, January 24th, 2002
6:30-7:00PM - Registration & Mixer
7:00-8:30PM - Program
8:30-8:45PM - Questions & Answers, Certificates
Goals & Objectives At the end of this presentation, the participant should be able to:
 
  1. Describe the pathophysiology of severe sepsis and causes of organ dysfunction.
  2. Describe the benefit of drotrecogin alfa (activated) therapy of sepsis.
  3. Evaluate the risks associated with drotrecogin alfa (activated) therapy.
Registration Information

Pre-Registration:

On Site Registration:  None

  Registration Closed Due to Capacity

First Name *
Last Name*
 Title*
Work
Position
Work Phone
Home Phone
FAX
E-mail*
Affiliation*
Message
Vegetarian Meal Requested?  (Portobello Mushroom)
 

* Required

An AES certificate for 1.0 hour of accredited continuing education will be awarded the evening of the program for California pharmacists completing the program.
For more info:  John Johnson, PharmD - SDCPhA/SDSHP CE Coordinator, VM.  760-875-7709, email:  education@sdcpha.com, PO Box 83834, San Diego, CA 92138, FAX  760-875-7709
Program Supported by Eli Lilly Pharmaceuticals